You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,322,084

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,322,084

Title:	Carrier-antibody compositions and methods of making and using the same
Abstract:	Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/225,504
Patent Claims:	1. A lyophilized composition comprising nanoparticle complexes having an outer surface, each of the nanoparticle complexes comprising: albumin; between about 100 to about 1000 anti-VEGF antibodies, each binding to the albumin via non-covalent hydrophobic bonds and having an Fc portion and a VEGF-binding portion wherein the VEGF-binding portion of the anti-VEGF antibodies is arranged on the outer surface of the complex; and paclitaxel; said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the nanoparticle complexes are capable of binding to VEGF in vivo and further wherein said complexes have an average size of less than 1 .mu.m. 2. The lyophilized composition of claim 1 that is stable at about 20.degree. C. to about 25.degree. C. for at least 3 months. 3. The lyophilized composition of claim 1, wherein each of the nanoparticle complexes comprises between about 400 and about 800 antibodies. 4. The lyophilized composition of claim 3, wherein less than 0.01% of nanoparticle complexes have a size greater than 800 nm. 5. The lyophilized composition of claim 1 wherein said nanoparticle complexes have an average size of about 160 nm. 6. The lyophilized composition of claim 1, wherein the albumin is human serum albumin. 7. The lyophilized composition of claim 1, wherein the nanoparticle complexes have a dissociation constant between about 1.times.10.sup.-11M and about 1.times.10.sup.-9M. 8. A lyophilized composition comprising nanoparticle complexes having an outer surface, each of the nanoparticle complexes comprising: albumin; between about 100 to about 1000 anti-VEGF antibodies, each binding to the albumin via non-covalent hydrophobic bonds and having an Fc portion and a VEGF-binding portion wherein the VEGF-binding portion of the anti-VEGF antibodies is arranged on the outer surface of the complex; and paclitaxel; said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the nanoparticle complexes are capable of binding to VEGF in vivo and further wherein said complexes have an average size of less than 1 .mu.m; wherein the lyophilized composition does not contain a bulking agent. 9. The lyophilized composition of claim 8 that is stable at about 20.degree. C. to about 25.degree. C. for at least 3 months. 10. The lyophilized composition of claim 8, wherein each of the nanoparticle complexes comprises between about 400 and about 800 antibodies. 11. The lyophilized composition of claim 10, wherein less than 0.01% of nanoparticle complexes have a size greater than 800 nm. 12. The lyophilized composition of claim 8, wherein said nanoparticle complexes have an average size of about 160 nm. 13. The lyophilized composition of claim 8, wherein the albumin is human serum albumin. 14. The lyophilized composition of claim 8, wherein the nanoparticle complexes have a dissociation constant between about 1.times.10.sup.-11M and about 1.times.10.sup.-9 M.

Details for Patent 10,322,084

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2034-10-06
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2034-10-06
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2034-10-06
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2034-10-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	2034-10-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003	⤷ Try a Trial	2034-10-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.